222 related articles for article (PubMed ID: 14620520)
41. Phosphate buffer interferes dissolution of prazosin hydrochloride in compendial dissolution testing.
Sudaki H; Fujimoto K; Wada K; Sugano K
Drug Metab Pharmacokinet; 2023 Aug; 51():100519. PubMed ID: 37393739
[TBL] [Abstract][Full Text] [Related]
42. Assessing the influence of media composition and ionic strength on drug release from commercial immediate-release and enteric-coated aspirin tablets.
Karkossa F; Klein S
J Pharm Pharmacol; 2017 Oct; 69(10):1327-1340. PubMed ID: 28703304
[TBL] [Abstract][Full Text] [Related]
43. Indomethacin-Kollidon VA64 Extrudates: A Mechanistic Study of pH-Dependent Controlled Release.
Tres F; Treacher K; Booth J; Hughes LP; Wren SA; Aylott JW; Burley JC
Mol Pharm; 2016 Mar; 13(3):1166-75. PubMed ID: 26845251
[TBL] [Abstract][Full Text] [Related]
44. Development of bicarbonate buffer flow-through cell dissolution test and its application in prediction of in vivo performance of colon targeting tablets.
Ikuta S; Nakagawa H; Kai T; Sugano K
Eur J Pharm Sci; 2023 Jan; 180():106326. PubMed ID: 36347443
[TBL] [Abstract][Full Text] [Related]
45. Feasibility studies of utilizing disk intrinsic dissolution rate to classify drugs.
Yu LX; Carlin AS; Amidon GL; Hussain AS
Int J Pharm; 2004 Feb; 270(1-2):221-7. PubMed ID: 14726137
[TBL] [Abstract][Full Text] [Related]
46. Miniaturized rotating disk intrinsic dissolution rate measurement: effects of buffer capacity in comparisons to traditional wood's apparatus.
Avdeef A; Tsinman O
Pharm Res; 2008 Nov; 25(11):2613-27. PubMed ID: 18648912
[TBL] [Abstract][Full Text] [Related]
47. Dissolution of carboxylic acids. III: The effect of polyionizable buffers.
Aunins JG; Southard MZ; Myers RA; Himmelstein KJ; Stella VJ
J Pharm Sci; 1985 Dec; 74(12):1305-16. PubMed ID: 4087198
[TBL] [Abstract][Full Text] [Related]
48. Toward Mechanistic Design of Surrogate Buffers for Dissolution Testing of pH-Dependent Drug Delivery Systems.
Blechar JA; Al-Gousous J; Wilhelmy C; Postina AM; Getto M; Langguth P
Pharmaceutics; 2020 Dec; 12(12):. PubMed ID: 33321933
[TBL] [Abstract][Full Text] [Related]
49. Low Buffer Capacity and Alternating Motility along the Human Gastrointestinal Tract: Implications for in Vivo Dissolution and Absorption of Ionizable Drugs.
Hens B; Tsume Y; Bermejo M; Paixao P; Koenigsknecht MJ; Baker JR; Hasler WL; Lionberger R; Fan J; Dickens J; Shedden K; Wen B; Wysocki J; Loebenberg R; Lee A; Frances A; Amidon G; Yu A; Benninghoff G; Salehi N; Talattof A; Sun D; Amidon GL
Mol Pharm; 2017 Dec; 14(12):4281-4294. PubMed ID: 28737409
[TBL] [Abstract][Full Text] [Related]
50. In Vitro Dissolution of Fluconazole and Dipyridamole in Gastrointestinal Simulator (GIS), Predicting in Vivo Dissolution and Drug-Drug Interaction Caused by Acid-Reducing Agents.
Matsui K; Tsume Y; Amidon GE; Amidon GL
Mol Pharm; 2015 Jul; 12(7):2418-28. PubMed ID: 25985298
[TBL] [Abstract][Full Text] [Related]
51. Quantification of kinetic rate law parameters for the dissolution of natural autunite in the presence of aqueous bicarbonate ions at high concentrations.
Gudavalli R; Katsenovich Y; Wellman D
J Environ Radioact; 2018 Oct; 190-191():1-9. PubMed ID: 29729585
[TBL] [Abstract][Full Text] [Related]
52. Predicting in vivo absorption behavior of oral modified release dosage forms containing pH-dependent poorly soluble drugs using a novel pH-adjusted biphasic in vitro dissolution test.
Heigoldt U; Sommer F; Daniels R; Wagner KG
Eur J Pharm Biopharm; 2010 Sep; 76(1):105-11. PubMed ID: 20472059
[TBL] [Abstract][Full Text] [Related]
53. Dissolution Profiles of Poorly Soluble Drug Salts in Bicarbonate Buffer.
Sakamoto A; Sugano K
Pharm Res; 2023 Apr; 40(4):989-998. PubMed ID: 37024757
[TBL] [Abstract][Full Text] [Related]
54. Solution-mediated phase transformation of salts during dissolution: investigation using haloperidol as a model drug.
Greco K; Mcnamara DP; Bogner R
J Pharm Sci; 2011 Jul; 100(7):2755-68. PubMed ID: 21328581
[TBL] [Abstract][Full Text] [Related]
55. Computer simulations using GastroPlus to justify a biowaiver for etoricoxib solid oral drug products.
Okumu A; DiMaso M; Löbenberg R
Eur J Pharm Biopharm; 2009 May; 72(1):91-8. PubMed ID: 19056493
[TBL] [Abstract][Full Text] [Related]
56. Instrumentation of Flow-Through USP IV Dissolution Apparatus to Assess Poorly Soluble Basic Drug Products: a Technical Note.
Paprskářová A; Možná P; Oga EF; Elhissi A; Alhnan MA
AAPS PharmSciTech; 2016 Oct; 17(5):1261-6. PubMed ID: 26573157
[TBL] [Abstract][Full Text] [Related]
57. Effects of gastric pH on oral drug absorption: In vitro assessment using a dissolution/permeation system reflecting the gastric dissolution process.
Kataoka M; Fukahori M; Ikemura A; Kubota A; Higashino H; Sakuma S; Yamashita S
Eur J Pharm Biopharm; 2016 Apr; 101():103-11. PubMed ID: 26873006
[TBL] [Abstract][Full Text] [Related]
58. Buffer solutions in drug formulation and processing: How pK
Samuelsen L; Holm R; Lathuile A; Schönbeck C
Int J Pharm; 2019 Apr; 560():357-364. PubMed ID: 30797864
[TBL] [Abstract][Full Text] [Related]
59. Buffer dependence of retinal glycolysis and ERG potentials.
Winkler BS
Exp Eye Res; 1986 Jun; 42(6):585-93. PubMed ID: 3720873
[TBL] [Abstract][Full Text] [Related]
60. Controlled release of acidic drugs in compendial and physiological hydrogen carbonate buffer from polymer blend-coated oral solid dosage forms.
Wulff R; Rappen GM; Koziolek M; Garbacz G; Leopold CS
Eur J Pharm Sci; 2015 Sep; 77():246-53. PubMed ID: 26093053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
